OOIR: Observatory of International Research

Papers

(The median citation count of Pharmacogenomics is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Identification of RNA Modification-Associated Single-Nucleotide Polymorphisms in Genomic Loci for Low-Density Lipoprotein Cholesterol Concentrations	45
Genetics and response to treatment with metformin for type 2 diabetes	28
Pharmacogenomics in Psychiatry – the Challenge of Cytochrome P450 Enzyme Phenoconversion and Solutions to Assist Precision Dosing	27
Evidence level for pharmacogenetic testing in antidepressant treatment: a systematic review	24
Pharmacogenomics for Prader-Willi syndrome: caregiver interest and planned utilization	19
miR-369-3p regulates the drug resistance of lung cancer cells by targeting PTPN12	15
Patient comprehension of preemptive pharmacogenomic results	14
How to implement pre-emptive pharmacogenetic testing in the acute hospital setting	13
Whole exome sequencing identifies rare variants involved in PPIX-metabolizing pathway in anti-TB drug-induced hepatitis	13
Pharmacogenomic variants affecting efficacy and safety of medicines acting on central nervous system among Sri Lankans	12
Assessing patient understanding of pharmacogenomic test results: a qualitative study	12
Contrasting ABCB1 Pharmacogenetics and Psychotropic Responses in Child and Adolescent Psychiatry: A case comparison	11
A systematic review of single nucleotide polymorphisms affecting allopurinol pharmacokinetics and serum uric acid level	11
Rapid point of care testing: the next frontier in pharmacogenomics	11
Assessing the Utility of Measurement Methods Applied in Economic Evaluations of Pharmacogenomics Applications	11
Severe systemic Adverse Reactions to Ophthalmic Timolol in a CYP2D6 Homozygous *4 Allele Carrier: A Case Report	10
Acceptance of recommendations by a pharmacogenetics clinic	10
Integrated in a Systems Pharmacology Approach, Pharmacogenetics holds the Promise for Personalized Medicine in Neonates	9
Pharmacogenetic markers and macrolide safety in influenza patients: insights from a prospective study	9
Characterization of CYP2C19 Pharmacogenetic Variation in African Populations and Comparison with Other Global Populations	9
Selpercatinib for RET-positive advanced pancreatic cancer detected by liquid biopsy: a case-based insight	9
CYP2D6 genotyping in a Korean cohort: comparative analysis with Asian, Caucasian, and African populations	9
Genetic polymorphisms and adverse reactions to antituberculosis therapy	8
UGT1A1 Genotype-Guided Dosing of Irinotecan: Time to Prioritize Patient Safety	8
A Survey of Physician Opinions in Russia in the Field of Pharmacogenetics of Cardiovascular Disease	8

Cost–Effectiveness of HLA-B58:01* Testing to Prevent Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis in Vietnam	8
Improving the Management of ALK-Rearranged Non-Small-Cell Lung Cancer Through a Mobile Application: A Physicians-Based Survey	8
Multiple Genetic Mutations Increase the Risk of Thrombosis Associated With Clopidogrel After Percutaneous Coronary Intervention	8
The cost–effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma	8
The Promise�of Digital Health in Healthcare Equity and Medication Adherence in the Disadvantaged Dementia Population	8
Workforce readiness for pharmacogenomics and key elements for sustainment within the Veterans Health Administration	8
Gene Polymorphisms Affect Postoperative Imatinib Plasma Levels and Edema in Adults With Gastrointestinal Stromal Tumor	8
Impact of genetic variants on fentanyl metabolism in major breast surgery patients: a candidate gene association study	7
A critical review of RAF inhibitors in BRAF-mutated glioma treatment	7
Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics	7
Genetika+: Precision Medicine Solutions for Mental Health	7
EFfects of UGT1A , CYP2C9/19 and ABAT Polymorphisms on Plasma Concentration of Valproic Acid in Chinese Epi	7
Effects of CYP3A4 and CYP2C9 Genotype on Systemic Anastrozole and Fulvestrant Concentrations in SWOG S0226	7
The Festival of Genetics and Personalized Medicine	6
Carbamazepine Cutaneous Adverse Reactions and HLA Gene Variation in the Chinese Population: A Systematic Review and Meta-Analysis	6
Accuracy and technical characteristics of CYP2C19 point of care tests: a systematic review	6
Barriers and facilitators for implementing a pharmacogenetic passport: lessons learned from reusing sequencing data	6
Association between CYP3A4 , CYP3A5 and ABCB1 Genotype and Tacrolimus Treatment Outcomes Among Allogeneic H	6
SLCO1B1 and ABCB1 Variants Synergistically Influence the Atorvastatin Treatment Response in South Indian Coronary Artery Disease Patients	6
TPMT and NUDT15 genotyping, TPMT enzyme activity and metabolite determination for thiopurines therapy: a reference laboratory experience	6
Pharmacogenomic implications of the differential distribution of CYP3A5 metabolic phenotypes among Latin American populations	6
DDX11-AS1 Modulates Dna Damage Repair to Enhance Paclitaxel Resistance of Lung Adenocarcinoma Cells	6
Predicting laboratory aspirin resistance in Chinese stroke patients using machine learning models by GP1BA polymorphism	6
Pharmacogenomics in Pediatric Medicine and Drug Development	5
Donor-Derived Cell Free DNA as a Biomarker in Kidney Transplantation	5
Genetic polymorphisms of OPRM1 on the Efficacy and Safety of Anesthetic and Analgesic Agents: A Systematic Review	5
Correction	5
Estimated clinical utility of multi-gene pharmacogenetic testing in a retrospective cohort of gynecology patients	5
Genetic risk factors for drug-induced long QT syndrome: findings from a large real-world case–control study	5
Exploring the Potential Benefits of Pharmacogenomics in Chronic Respiratory Diseases	5
Patient Satisfaction With Return of Pharmacogenomic Results Utilizing a Patient Portal Message	5
Knowledge and Attitudes of Incoming Pharmacy Students Toward Pharmacogenomics and Survey Reliability	5
Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversion	5
The Genetics of Drug-Induced Qt Prolongation: Evaluating the Evidence for Pharmacodynamic Variants	5
XDH Genotypes Through Gene–Gene Interactions with NUDT15 Affect Azathioprine-Induced Leukopenia in Chinese Patients	5
Genome-Wide Association Study of Liver Enzyme Elevation in an Extended Cohort of Rheumatoid Arthritis Patients Starting Low-Dose Methotrexate	4
Clinically actionable genetic variation in patients with or at high-risk of cardiovascular diseases from the Montreal Heart Institute	4
Liquid biopsy: an essential tool for metastatic breast cancer’s follow-up	4
Impact of CYP2C19 Gene Polymorphisms on Warfarin Dose Requirement: A Systematic Review and Meta-Analysis	4
Pharmacogenomics: A Tool to Improve Medication Safety and Efficacy in Patients with Cystic Fibrosis	4
The Frequency Of Rs2231142 in ABCG2 Among Native Hawaiian nd Pacific Islander Subgroups: Implications for Personalized Rosuvastatin Dosing	4
Association of CYP2C19 , CYP3A4 and ABCC2 Polymorphisms and Voriconazole Plasma Concentrations in Uygur Ped	4
Artificial intelligence, medications, pharmacogenomics, and ethics	4
Psychiatric Level 1A Evidence Pharmacogenomics in a Brazilian Admixed Cohort and Global Populations	4
Leveraging Clinical Decision Support to Reduce the Risk of Discordant Pharmacogenomics Results	4
The Revolution of Pharmaco-Omics: Ready to Open new Avenues in Materializing Precision Medicine?	4
Pharmacogenomic curriculum in Australian medical schools: a content analysis study	4
Overview of the Year 2023 at Pharmacogenomics	4
DPYD Genotyping and Predicting Fluoropyrimidine Toxicity: Where do we Stand?	4
Single-Nucleotide Polymorphisms in ABC Drug Transporters Alter Expression and Circulating Tenofovir in Healthy South African Women Exposed to Pre-Exposure Prophylaxis	4

Congruence Rates for Pharmacogenomic Noninterruptive Alerts	4
The Importance of Phenoconversion when using the CYP2D6 Genotype in Clinical Practice	4
Healthcare Professionals’ Knowledge, Confidence and Perceptions of Pharmacogenomics in Primary Care and Pain Management	4
Variation in the ABC transporter genes and association with clinical outcomes in colorectal cancer: a brief review	4
Impact of ABCB1 gene polymorphism on clopidogrel plasma concentration and cardiovascular events in post-PCI patients	4
Relevance of NAT2 Genotype and Clinical Factors to Risk for Antituberculosis Drug-Induced Liver Injury	4
Influence of CYP3A5 , IL-10 Polymorphisms and Metabolism Rate on Tacrolimus Exposure in Renal Post-Transplant Recipients	4
CYP2C:TG haplotype in Ecuador and Nicaragua: insights into CYP2C19 genotype–phenotype correlation in context to Mestizo popula	4
Posttransplantation diabetes mellitus (PTDM): pharmacological aspects and genetic predispositions	4
Evaluation of Pentamidine Tolerability and Efficacy Between CYP2C19 Phenotypes	4
Pharmacogenetics of Calcineurin inhibitors in kidney transplant recipients: the African gap. A narrative review	4
Clinical Pharmacology and Pharmacogenomics for Implementation of Personalized Medicine	4
Effect of UGT1A6 and UGT2B7 polymorphisms on the valproic acid serum concentration and drug-induced liver injury	3
Pharmacogenomics Implementation: “ A Little Less Conversation, a Little More Action, Please ”	3
A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder	3
Knowledge and perceptions of pharmacogenomics among pharmacists in Manitoba, Canada	3
Reinterpretation of pharmacogenomic phenotypes after combinatorial psychiatric testing	3
Genetic Variants of the Nuclear Factor Erythroid 2-Related Factor 2/Antioxidant Reaction Element Pathway on the Risk of Antituberculosis Drug-Induced Liver Injury: A Systematic Review	3
From genomics to clinic: the transformative impact of AI in pharmacogenomics and personalized medicine	3
Pharmacogenetic Informed Care in Early Childhood: Options for Improving Access and Health Equity	3
lncRNA MALAT1 Regulates the Resistance of Breast Cancer Cells to Paclitaxel Via the miR-497-5p/ SHOC2 axis	3
Genetic polymorphism associated with non-response to therapy in inflammatory bowel disease patients: a review	3
Pharmacogenomics of anthracycline-cyclophosphamide-taxane chemotherapy: an influence of CYP polymorphisms and BMI on breast cancer treatment outcomes	3
Pharmacogenomic Variants Affecting Efficacy and Toxicity of Statins in a South Asian Population from Sri Lanka	3
The pharmacogenetics of rosuvastatin and implications for treatment: a systematic review	3
ABCB1 and OPRM1 Single-Nucleotide Polymorphisms Collectively Modulate Chronic Shoulder Pain and Dysfunction in South African Breast Cancer Survivors	3
Analysis of the Difference in SLCO1B1 and APOE Gene Polymorphisms Between Mongolian and Han Populations	3
Implication of KDM6A in Bladder Cancer	3
Pharmacogenetic markers of PEG-asparaginase toxicity in Brazilian pediatric ALL: insights from a multicenter prospective cohort study	3
Influence of Polymorphisms in CYP2C9 , VKORC1 , MDR1 and APOE Genes on the W	3
Pharmacogenomic testing for Prader-Willi syndrome: a mixed methods analysis of caregiver experiences and utilization	3
Cancer genetics and response to oncolytic virus treatment for ovarian cancer	3
Integrating Pharmacogenomic Testing Into Paired Germline and Somatic Genomic Testing in Patients with Cancer	3
Effects of genetic and clinical factors on thiopurine drugs pharmacokinetics in Tunisian patients	3
Acute hemolytic anemia and methemoglobinemia in a pediatric oncology patient with G6PD deficiency: a case report	3
The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress	3
Exploring precision medicine by utilizing individual genetic information for the management of Alzheimer’s disease	3
Targeting RET mutation in medullary thyroid cancer	3
Pharmacogenetic Variants Influence Vitamin K Anticoagulant Dosing in Patients with Mechanical Prosthetic Heart Valves	3
Pharmacogenomics education among professional societies: assessing practices and future needs	3
Evaluation of pharmacogenetic automated clinical decision support for clopidogrel	2
Implementation of clopidogrel pharmacogenetics: a Brazilian perspective	2
Warfarin Pharmacogenomics in African Populations: The Importance of Ethnicity-Based Algorithms	2
Challenges for the Application of Pharmacogenomics Associated with the Nomenclature of Allelic Variants	2
Impact of CYP2C19 polymorphism testing on the risk of stent thrombosis in patients with carotid artery stenting	2
Treatment of extended RAS/ BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations	2
Opportunities and challenges for the implementation of pharmacogenomics in supportive care for gastrointestinal cancer patients in Zimbabwe	2
Application of Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma	2
Considering Medication Exposure in Genomic Association Studies of Cognition in Psychotic Disorders	2
Pharmacogenetics of 6-Mercaptopurine in a Black Zimbabwean Cohort Treated for Acute Lymphoblastic Leukaemia	2
Identification of Clinical and Pharmacogenetic Factors Influencing Metformin Response in Type 2 Diabetes Mellitus	2
Progression of Precision Statin Prescribing for Reduction of Statin-Associated Muscle Symptoms	2
Characterizing models for delivery of pharmacogenomic testing: a scoping review	2
SLCO1B3 T334G Polymorphisms and Mycophenolate Mofetil-Related Adverse Reactions in Kidney Transplant Recipients	2
Effects of MDR1 and OPRM1 Genetic Polymorphisms on the Pharmacodynamics of Propofol–Remifentanil TIVA in Pediatrics	2
Association Between Genetic Variants and the Risk of Nivolumab-Induced Immune-Related Adverse Events	2
Breast Cancer Pharmacogenetics: A Systematic Review	2
The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer	2
Impact of the PEAR 1 Polymorphism on Clinical Outcomes in Chinese Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Interventio	2
Application of Pharmacogenomics in Supportive Oncology: A Patient Journey	2
Pharmacogenetic and Pharmacogenomic Treatment of Rheumatoid Arthritis: A Review of Pharmacogenomics Knowledge Base Scientific Evidence	2
Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic	2
Pharmacogenomics of Hydroxyurea Therapy and Fetal Hemoglobin Levels in Sickle Cell Anemia	2
IL16 and Factor V Gene Variations are Associated with Asparaginase-Related Thrombosis in Childhood Acute Lymphoblastic Leukemia Patients	2
Effects of immunorelated gene polymorphisms on trastuzumab targeting breast cancer cell in vitro	2
Patient and provider perceptions of pharmacogenetic testing in gynecologic surgery: a cross-sectional analysis	2
Polymorphism of CYP3A418* is associated with anti-tuberculosis drug-induced hepatotoxicity	2
Scoping review of associations between cytochrome P450 3A4/5 single nucleotide polymorphisms and risk factors for fentanyl overdose	2
Pharmacogenomic markers associated with drug-induced QT prolongation: a systematic review	2
Exploring the potential of pharmacogenetic testing in Alabama Veterans diagnosed with major depressive disorder	2
SALL4 upregulates brain-derived neurotrophic factor to mediate Hedgehog signaling to inhibit carboplatin sensitivity in colon adenocarcinoma	2
TPMT Gene Polymorphisms (c.238G>C, c.460G>A and c.719A>G) in a Healthy Venezuelan Population	2
The genomic landscape of CYP2D6 variation in the Indian population	2
Antiplatelet Therapy Guided by CYP2C19 Point-of-Care Pharmacogenetics Plus Multidimensional Treatment Decisions	2
Glaucoma diagnosis and treatment in the era of precision medicine	2